One of the treatments being developed by Israel’s Can-Fite (see here) is CF-101 (Piclidenoson) which is in Phase 2 & 3 trials for psoriasis, rheumatoid arthritis and other diseases. Can-Fite is shortly to commence a Phase 2 trial of CF-101 on Covid-19 patients.
From psoriasis to Covid-19
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.